siRNA therapy decreases triglycerides in patients with uncommon ailment
.RESEARCH HIGHLIGHT.19 September 2024.
Plozasiran reduced triglyceride levels through 80% and also lowered the danger of pancreatitis in patients along with persistent chylomicronemia, along with or without a hereditary prognosis.